Liver Cancer, Sarcopenia
Conditions
Keywords
liver cancer, sarcopenia, lenvatinib, immune therapy, prognosis
Brief summary
Sarcopenia is associated with the prognosis of HCC and cholangiocarcinoma. But there has been rare study focusing on the effect of sarcopenia on the prognosis of HCC treated with lenvatinib and anti-PD1.
Detailed description
By tracking the short-term and long-term results of HCC patients treated with lenvatinib and anti-PD1,the difference of short-term results between patients with sarcopenia and patients without sarcopenia was analyzed, and the correlation between sarcopenia and short-term and long-term results of patients after systemic treatment was explored, so as to improve people's awareness of sarcopenia and pay attention to its prevention and treatment.All implementation details are based on the newest EWGSOP definition. The investigators consecutively admitted patients the questionnaire and evaluated the assessment of muscle strength (grip strength test and chair stand test), muscle quantity (L3 plane total skeletal muscle area) and physical performance (gait test) following the F-A-C-S approach, to confirm patients with sarcopenia accurately. And by tracking the short-term and long-term outcomes, the differences were analyzed and the relationship between sarcopenia and prognosis of systemic treatment was explored.
Interventions
DIAGNOSTIC_TESTgait speed; ct scan; grip strength and chair stand test
The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
Sponsors
The First Affiliated Hospital of Zhejiang Chinese Medical University
Eastern Hepatobiliary Surgery Hospital
Qilu Hospital of Shandong University
First Affiliated Hospital of Wenzhou Medical University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Patients with clinical diagnosis of liver cancer * No cancer other than liver cancer has been diagnosed * Age ≥18 years
Exclusion criteria
* Patients who could not complete the standard tests and questionnaires * Patients received other therapies * Patients who had other causes of muscle weakness (injury, fracture, stroke, etc.) * Patients who missing CT data or CT scan did not reach the level of the third lumbar vertebra (L3)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Short-term results | 3 months | Post-treatment complications |
| Long-term results | 2 years | Overall survival; Progression free survival |
Countries
China
Outcome results
None listed